Dynamic Treatment Stratification Using ctDNA.

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-030-26439-0_14PMID 31605234
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial

  2019cited by this paper
• Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial

  2018cited by this paper
• Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

  2018cited by this paper
• Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR‐Mutant Lung Adenocarcinoma

  2018cited by this paper
• Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

  2018cited by this paper
• Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients

  2017cited by this paper
• Cancer statistics, 2017

  2017cited by this paper
• Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

  2017cited by this paper
• Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study

  2017cited by this paper
• iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

  2017cited by this paper
• K.D. Miller, and A.

  2017cited by this paper
• Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.

  2017cited by this paper
• Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

  2016cited by this paper
• Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations

  2016cited by this paper
• Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab

  2016cited by this paper
• Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma

  2016cited by this paper
• Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.

  2015cited by this paper
• Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

  2015cited by this paper
• Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer

  2015cited by this paper
• Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.

  2015cited by this paper
• Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.

  2015cited by this paper
• Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients

  2015cited by this paper
• Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

  2015cited by this paper
• Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

  2015cited by this paper
• PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials

  2015cited by this paper
• Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

  2015cited by this paper
• Abstract 5606: Detection of circulating tumor DNA in early and late stage human malignancies

  2014cited by this paper
• Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade

  2014cited by this paper
• Liquid biopsies: genotyping circulating tumor DNA.

  2014cited by this paper
• Quantitative Cell-Free Circulating BRAF Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors

  2014cited by this paper
• Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA

  2013cited by this paper
• Analysis of circulating tumor DNA to monitor metastatic breast cancer.

  2013cited by this paper
• Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

  2013cited by this paper
• The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

  2012cited by this paper
• Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

  2012cited by this paper
• Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

  2012cited by this paper
• Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

  2011cited by this paper
• Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas

  2011cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• B.A. Chabner, D.L. Longo (eds.) Cancer Chemotherapy and Biotherapy: Principles and Practice

  2002cited by this paper

• Circulating tumor DNA (ctDNA) application in investigation of cancer: bench to bedside.

  2024cites this paper
• Reviewing the progress of cancer research in the USA

  2024cites this paper
• Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications

  2023cites this paper
• An Overview: Genetic Tumor Markers for Early Detection and Current Gene Therapy Strategies

  2023cites this paper
• Clinical utility of analyzing circulating tumor DNA in patients with non-small cell lung carcinoma

  2022cites this paper
• Cancer evolution: Darwin and beyond

  2021cites this paper
• Future Directions in the Use of SAbR for the Treatment of Oligometastatic Cancers.

  2021cites this paper
• The Provocative Roles of Platelets in Liver Disease and Cancer

  2021cites this paper
• Properties and Application of Cell-Free DNA as a Clinical Biomarker

  2021cites this paper
• Liquid biopsy: the current state of the issue

  2021cites this paper
• Liquid biopsy in ovarian cancer.

  2020cites this paper
• Ready-to-use nanopore platform for the detection of any DNA/RNA oligo at attomole range using an Osmium tagged complementary probe

  2020cites this paper
• Liquid biopsy in endometrial cancer

  2020cites this paper